موافقات الدواء

Multiple Sclerosis (MS)
It is indicated as single disease modifying therapy in adults with highly active relapsing
remitting multiple sclerosis (RRMS) for the following patient groups:
• Patients with highly active disease despite a full and adequate course of treatment with at least
disease modifying therapy (DMT).
Or
• Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in
year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging
(MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.